Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial.
10.12122/j.issn.1673-4254.2020.10.15
- Author:
Xiaowei CHEN
1
;
Yiyue JIANG
1
;
Ying ZHANG
1
;
Wencong DAI
1
;
Rong FAN
1
;
Xie WENG
2
;
Peng HE
1
;
Feifei YAN
2
;
Yabing GUO
1
Author Information
1. Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
2. Cancer Center, Hospital of Integrated Traditional and Western Medicine, Southern Medical University, Guangzhou 510310, China.
- Publication Type:Randomized Controlled Trial
- Keywords:
advanced hepatocellular carcinoma;
hand-foot skin reaction;
nursing intervention;
ozone oil;
sorafenib
- MeSH:
Antineoplastic Agents/therapeutic use*;
Carcinoma, Hepatocellular/drug therapy*;
Hand-Foot Syndrome/prevention & control*;
Humans;
Liver Neoplasms/drug therapy*;
Niacinamide/therapeutic use*;
Ozone/therapeutic use*;
Phenylurea Compounds/adverse effects*;
Quality of Life;
Sorafenib/therapeutic use*
- From:
Journal of Southern Medical University
2020;40(10):1488-1492
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the effects of medical ozone oil and urea ointment for prevention and treatment of hand-foot skin reaction (HFSR) caused by sorafenib in patients with hepatocellular carcinoma (HCC).
METHODS:A total of 99 patients diagnosed with advanced HCC according to National Comprehensive Cancer Network (NCCN) who were scheduled to receive sorafenib treatment for the first time were enrolled in this study between April, 2018 and January, 2020. The patients were randomized into medical ozone oil group (
RESULTS:Eight patients were excluded for poor compliance or protocol violations, leaving a total of 91 patients for analysis, including 44 in medical ozone oil group and 47 in urea ointment group. Sixteen (36.4%) of patients in ozone oil group developed HFSR, a rate significantly lower than that in urea ointment group (57.4%;
CONCLUSIONS:Medical ozone oil can significantly reduce the incidence and severity of HFSR to improve the quality of life of HCC patients receiving sorafenib treatment.
